Hyperfine, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| HYPR | NNOX | VREX | MDX.V | LAB | PROF | |
|---|---|---|---|---|---|---|
| Market cap | 79.57M | 22.21M | 786.00M | 16.40M | 243.14M | 261.63M |
| P/E (TTM) | — | — | 34.9 | — | — | — |
| Forward P/E | -2.4 | -0.7 | 17.3 | — | -61.6 | -12.2 |
| Price/book | 2.2 | 0.3 | 1.6 | -1.5 | 0.4 | 5.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −38.76% | −91.05% | +55.68% | −16.67% | −44.64% | +22.39% |
| Today | +8.36% | −7.66% | −0.11% | 0.00% | +0.85% | +2.43% |
The closest companies by business and industry (Medical Devices). Prices may be delayed up to 15 min.
Latest news
All HYPR news ›Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings
Since the Swoop system does not require the shielding that conventional high-field MRI systems depend on, it can scan in electromagnetically noisy environments, such as intensive care units and ...
Hyperfine Q4 2025 Results: Revenue Exceeds $5M on Swoop System Strength
The call included standard cautionary statements regarding forward-looking information. Management indicated that such statements involve material risks and uncertainties that could cause actual results to differ. The information presented…
Hyperfine expects Q3 revenue of $6M; shares jump 9%
Hyperfine (HYPR) Q3 revenue seen at $6.0M vs $5.13M consensus, with improved cash burn and 2026 guidance. Hyperfine (HYPR) announced Thursday that its preliminary, unaudited Q3 revenue is expected to be approximately $6.0 million versus a…
Hyperfine Reports Preliminary Q3 Revenue of Approximately $6.0 Million
Hyperfine (HYPR) reported preliminary, unaudited third-quarter 2026 revenue of approximately $6.0 million for the period ended September 30, up 53% sequentially. The company said revenue is expected to exceed net cash burn for the first…
Hyperfine, Inc. to Announce Third Quarter 2026 Financial Results on November 9, 2026
Magnetic resonance imaging (MRI) is a medical scan that uses magnetic fields and radio waves to create detailed pictures of the inside of the body, like a high-resolution camera for tissues and organs. Investors care because MRI drives…
Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million
A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public…
Analyzing Beta Bionics (NASDAQ:BBNX) & Hyperfine (NASDAQ:HYPR)
Posted by Sarita Garza on Oct 7th, 2026 Hyperfine (NASDAQ:HYPR – Get Free Report) and Beta Bionics (NASDAQ:BBNX – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- stocktitan.net2
- indexbox.io1
- markets.financialcontent.com1
- quiverquant.com1
- seekingalpha.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.